UCL Institute of Cardiovascular Science
- Myocardial disease
- Structural heart disease
- Vascular disease
- Cardiovascular genetics
- Regenerative medicine
- Genetic epidemiology and translational cardiovascular genomics
- Preventions and outcomes
- News & events
- Contact us
Percutaneous coronary interventions
The build-up of cholesterol-laden plaques in the coronary arteries can lead to angina, myocardial infarction, or heart failure. Percutaneous coronary intervention (PCI), commonly known as angioplasty and stenting, is one of the therapeutic procedures used to treat coronary artery disease.
At the Heart Hospital, Dr Meier’s focus is on percutaneous coronary
interventions and research into future technologies in Interventional Cardiology
such as new stents and drugs. He is
currently leading the Yale – UCL Device Development Programme and is an
associate editor for the journal “Heart”.
Key research activities
One of Dr Meier’s key areas of focus is on the evaluation of new
therapies and devices in the Interventional Cardiology arena. Dr Meier is
working closely with Yale University (New Haven, CT, USA) in the Yale-UCL
Collaborative to develop and test new cardiovascular devices for the future.
The collateral circulation of the heart is a system of small inter-connecting
vessels which can be regarded as ‘natural bypasses’. The aim is to find ways to
therapeutically induce the growth of such collateral to reduce the burden of
coronary artery disease. Researchers from UCL, University of Bern, Yale
University and other international collaborators examined the role of natural
bypass vessels called coronary collaterals in patients with blocked arteries. The
study, published in the European Heart Journal, shows patients with lots
of these vessels have a 36% reduced risk of mortality, highlighting their
importance as a therapeutic target.
For an updated list of publications visit www.drpascalmeier.com